10/23/2019 4:08:50 PM
BioMarin Q3 EPS $0.30 Vs. Loss $0.07 Year Ago
9/26/2019 8:39:19 AM
BioMarin Submits Clinical Trial Application In U.K. For Investigational Gene Therapy For PKU
8/1/2019 4:22:00 PM
BioMarin Q2 Loss/share $0.21 Vs. Loss $0.09 Year Ago
7/10/2019 6:50:34 AM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $128 Price Target
7/9/2019 8:32:29 AM
BioMarin Appoints Liz McKee Anderson To Board, Effective July 15
7/8/2019 8:03:57 AM
BioMarin Plans To Submit For Authorization Of Valoctocogene Roxaparvovec To Treat Severe Hemophilia A In Q4 In US,EU
6/21/2019 11:37:39 AM
BioMarin Earns Milestone Payments From Pfizer For TALZENNA
6/19/2019 1:15:19 PM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $128 Price Target
6/18/2019 8:33:15 AM
BioMarin : Vosoritide Phase 2 Study Shows Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia
6/4/2019 8:32:22 AM
BioMarin Announces Approval Of Vimizim In China For Treatment Of Morquio A Syndrome
5/28/2019 7:00:12 AM
BioMarin'Phase3 Cohort Of Valoctocogene Roxaparvovec,Gene Therapy Study In Severe Hemophilia A Met PreSpecified Criteria
5/28/2019 6:53:15 AM
BioMarin Provides 3 Years Of Data From Phase1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A
5/6/2019 10:15:36 AM
BioMarin Pharma : EU Approves Palynziq For Treatment Of Phenylketonuria In Patients Aged 16 Years Or Older